David Ferreira: Insights from the 1st National Meeting of Young Immunohematologists in Abrantes
David Ferreira, President of the General Assembly of APIH, shared a post on LinkedIn:
”Thrombophilia isn’t a diagnosis. It’s the starting point for a clinical decision-making challenge.
Today I attended the 1st National Meeting of Young Immunohematologists in Abrantes, participating in a ‘hot seat’ session on thrombophilia and thrombosis.
Open discussion, different perspectives – but aligned on the essentials: making the right decision is harder than knowing a lot.
This is where the specialty grows.
A big thank you to the organizers for the invitation and, above all, for the quality of the conference.
For a first edition, it was frankly very well done – scientific, dynamic, and with real space for debate.
This is how a new generation with critical thinking is formed.
Thanks also to my panel colleagues for the challenging and productive discussion:
Dr. Rita Pardal, Dr. Catarina Guedes, Dr. Luciana Gonçalves, and Dr. Sofia Ribeiro.
In thrombosis, the risk isn’t just in the event itself.
It’s in the decision.
Congratulations to everyone involved. This has to continue!!!”

Stay updated with Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering